PL-005 Bioprospecting for potent anti-tuberculosis compounds from microbial natural product library  by Guo, H. & Zhang, L.X.
Free Paper Presentation 5: Tuberculosis S25
OL-030 Cloning of eae genes of Escherichia coli
O157:T in pGEMT easy vector as DNA vaccine
candidate
M. Golshan1 *, M. Kargar1, A. Doosti2. 1Department of
Microbiology, Jahrom Branch, Islamic Azad University,
Jahrom, Iran, 2Biotechnology Research Center, Shahrekord
Branch, Islamic Azad University, Shahrekord, Iran
Background: Escherichia coli O157:H7 is associated with
hemorrhagic colitis, thrombotic thrombocytopenic purpura,
and hemolyticuremic syndrome in humans. In addition
to producing Shiga-like (Vero) toxin and enterohemolysin,
E. coli O157:H7 has been shown to attach to the cytoplasmic
membranes of intestinal epithelial cells, to efface their
microvilli, and to cause actin to accumulate beneath sites
of bacterial attachment. These features are shared with
several other enterohemorrhagic E. coli (EHEC) serotypes
and members of the enteropathogenic E. coli (EPEC) group.
The eae gene, which has been shown to be necessary for
attaching and effacing activity, encodes a 94- to 97-kDa
outer membrane protein (OMP) which is termed intimin.
This gene is located in a chromosomal pathogenicity island
also known as the locus of enterocyte effacement (LEE).
The gold aim of this study was cloning of eae gene of E. coli
O157:T in E. coli TOP10F strain.
Methods: The eae gene was isolated from total genome of
E. coli O157:T by PCR and eae speciﬁc PCR primers. DNA
fragment of eae gene was cloned by T/A cloning technique
in pGEMT easy vector (Invitrogen, San Diego, Calif.), and
this construct transformed into E. coli TOP10F strain.
Results: The results show that, eae was cloned in E. coli
successfully. The sequencing result conﬁrm that eae gene
was cloned is correct and BLAST outcome demonstrated the
sequences of eae is approved.
Conclusions: Therefore it seems that the DNA constract
that was produced in this study can be used for DNA vaccine
against eae of E. coli O157:T in future researchs.
OL-031 In vivo investigation of Killed Leishmania
Vaccine’s (KLV) efﬁcacy with Imiquimod (IMQ)
as adjuvant in inhibition of visceralization of
Leishmania major in Balb/c model
E. Salehizadeh1, H. Nahrevanian2 *, M. Farahmand2,
R. Hajihosseini1, M.H. Alimohammadian3, R. Saghiri4,
S. Naeimi2. 1Payame Nour University, Tehran Unit, Tehran,
Iran, 2Department of Parasitology, Pasteur Institute
of Iran, Tehran, Iran, 3Department of Immunology,
Pasteur Institute of Iran, Tehran, Iran, 4Department of
Biochemistry, Pasteur Institute of Iran, Tehran, Iran
Background: KLV have been applied for its immunogenicity
in human and mice model. IMQ as adjuvant is
inducing humoral and cellular immune responses during
leishmaniasis. In this study, both KLV and IMQ were applied
in order to investigate the inhibition rate of L. major
replication and visceralization in mice.
Methods: Promastigotes of L. major were harvested
from culture, counted and used to infect Balb/c mice.
Primarily, mice were injected with KLV/IMQ, and then
they were infected by L. major intradermally with 2×106
promastigotes. Six weeks after infection, a small nodule
was appeared leading to a large lesion and visceralisation.
Effects of KLV/IMQ, physiopathological changes, lesion size,
delay of lesion formation, proliferation of amastigotes inside
MQs and detection of amastigotes in target organs were also
studied.
Result: Data analysis of body weight, rate of
hepato/splenomegaly, and survival rate indicated no
signiﬁcant differences among experimental groups. It is
concluded that both KLV and IMQ represented no cytotoxic
effects on the host, but they partly increased lesion
size; and impressed number of amastigotes inside MQs.
Application of KLV/IMQ decreased visceralization in liver and
induced liver, spleen and plasma NO. Although, application
of IMQ solely decreased visceralization in lymph nodes, but
KLV/IMQ represented no effects in concentrations of plasma
Cu/Zn and it increased liver SGOT and SGPT.
Conclusion: Unlike topical application of IMQ, injectable
IMQ presented no ameliorative affects on CL. IMQ efﬁcacy
may be associated with route, dose and number of injection,
which require more investigations.
OL-032 Expression of mRNA and protein of Fas
associated death domain protein in fulminant
hepatic failure model and the relationship of
hepatocytes apoptosis
H.Y. Ge, Z. Zhen*. Department of infection disease, The
Third Hospital of Hebei Medical University, Shijiazhuang,
China
Objective: It has been conﬁrmed that Fas associated death
domain protein (FADD) participated in many death signal
pathways induced by death receptor and has an connection
role in apoptosis signal pathway. To study the expression
of protein and mRNA of Fas associated death domain
protein (FADD) in fulminant hepatic failure (FHF) induced
by D-galactosamine (D-GalN)/lipopolysaccharide (LPS) and
the relationship of hepatocytes apoptosis.
Methods: The sensitized Wistar rat in the model group was
injected by LPS and D-GalN to induced fulminant hepatic
failure; the control group was given the same volume
physiological saline. The expression of protein and mRNA
of FADD were detected by immunohistochemistry and RT-
PCR and hepatocyte apoptosis was examined by common HE
stain and ﬂow cytometry.
Results: The liver histopathology showed apoptosis body and
inﬁltration of inﬂammatory cells after 4 h of intraperitoneal
injection of D-Gal/LPS, the hepatocyte apoptosis reached
the peak at 12 h. At 24 h hepatocyte apoptosis evidently
decreased subsequent hepatocytes necrosis occupied the
important position. The apoptotic rate reached to 27%
at 12 h. The expression of protein and mRNA of FADD
prominent were dramaticlly increased positively correlative
with hepatocyte apoptosis in D-GalN/LPS group compared
with control group.
Conclusions: The expession of FADD remarkably increased
in FHF and be closely related with hepatocyte apoptosis.
Scientiﬁcally regulation of the expression FADD may play an
important role in prevention and treatment of FHF.
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PL-005 Bioprospecting for potent anti-tuberculosis
compounds from microbial natural product
library
H. Guo1, L.X. Zhang1 *. 1IMCAS, China
Mycobacterium tuberculosis is second only to AIDS as one
of the world’s most signiﬁcant and devastating pathogens,
which has infected over one-third of world’s population, and
causes 2 million deaths annually. In the face of the catas-
trophic synergy between HIV and TB and the emergence of
MDR and XDR-MTB strains, new drugs for the chemotherapy
of tuberculosis are urgently needed. Microbial Natural
Products or their derivatives have been an important
S26 Abstracts, 5th DICID
source for most antibiotics on the market today, including
the ﬁrst-line and salvage TB regimens, including rifampin,
streptomycin, amikacin and etc. A set of Microbial Natural
Product Library (MNPL) containing secondary metabolites
from a unique collection of actinomycetes and fungal
strains from un- or under-explored ecological niches in China
has been constructed. A pilot screen for potential anti-TB
compounds was conducted with a selection of 5,000 extracts
samples from this MNPL, utilizing a GFP labeled M. bovis
BCG based HTS model (Z’-factor 0.8, CV < 15%, throughput
60,000 wells/day). 80 out of the 5,000 extracts showed
>90% inhibition against logarithmically growing BCG were
further evaluated on M. tb H37Rv strains at Broad Institute,
as a dilution series ranging from 1× to 1/128×. The
results showed that 46 extracts demonstrated anti-H37Rv
activity, with 8 showing activity at 1/16×, and 1 showing
activity at 1/128×. The following large scale fermentation
and bioactivity guided compound isolation work lead to
the discovery of diversiﬁed class of anti-TB compounds,
including actinomycins (MIC 1 4 ug/ml), quinomycins (MIC
0.5 ug/ml), nanaomycins (MIC 8 ug/ml), cyclopeptides (MIC
2 8 ug/ml), anthraquinones (MIC 4 8 ug/ml), oligomycins,
part of which were new compounds (not listed).
OL-033 Etambutol-mediated changes in rat liver
cytochrome P-450 isoforms expression and
DNA-fragmentation processes
S. Anisimova1 *, G. Shayakhmetova1, L. Bondarenko1,
V. Kovalenko1. 1SI “Institute of Pharmacology & Toxicology”
National Academy of Medical Sciences of Ukraine, Kyiv,
Ukraine
Objectives: Etambutol is one of ﬁrst-line antitubercular
drugs in current therapeutic regimens. Its main
disadvantage is wide spectrum of adverse effects which can
lead to therapeutic failure. The aim of present study was to
investigate etambutol effects on rat liver cytochrome P-450
isoforms expression and DNA-fragmentation processes.
Methods: Wistar albino male rats (160 200 g b.w.) were
divided into two groups: I received etambutol per os at a
dose of 155mg/kg b.w./day, II control. After 60 days of the
experiment, rats were sacriﬁced via cervical dislocation.
Expression of rat liver CYP2E1, CYP3A2 and CYP2C23
were studied by RT-PCR methods. DNA fragmentation was
investigated electrophoretically.
Results: Our data demonstrated etambutol-mediated
quantitative and qualitative changes in male rat DNA
fragmentation and expression of CYP2E1, CYP3A2 and
CYP2C23 in comparison with control. CYP2E1 and CYP3A2
expression increasing was accompanied with CYP2C23
expression inhibition. DNA fragmentation processes were
also greatly intensiﬁed at etambutol treatment. Its
introduction caused appearance of new fractions with
longer DNA-fragments (above 1000 b.p., 1000 800 b.p. and
800 600 b.p.). Among shorter DNA-fragments main fraction
contained chains with 20 30 b.p.
Conclusion: Thus etambutol treatment caused adverse
effects in organisms on the level of cytochrome P-450
isoforms expression and DNA-fragmentation processes.
Extensive investigation of etambutol and cytochrome P-450
system interactions allowed to prevent or correct this
antitubercular agent adverse effects.
OL-034 A comparison study of extrapulmonary and
pulmonary tuberculosis in Hong Kong
S.S. Lamb1 *, I.F. Hung1, K.K. To1. 1Queen Mary Hospital,
Hong Kong SAR, China
Background: This study examines the differences between
culture positive extrapulmonary and pulmonary tuberculosis
(TB) patients. It correlates these ﬁndings with the current
understanding of extrapulmonary TB. It looks at how these
factors affect mortality at six months and at the role of
underlying diseases in drug resistance.
Method: This is a two year retrospective study comparing
115 extrapulmonary TB patients with 115 pulmonary TB
patients.
Results: Extrapulmonary patients were younger than
pulmonary patients with a median age of 53 years versus
73 years (p < 0.001). They presented more commonly
with lymphadenopathy (p < 0.001). More extrapulmonary
patients had chronic renal failure (p < 0.002) and Human
Immunodeﬁciency Virus (HIV) infection (p = 0.005). They had
a higher median erythrocyte sedimentation rate (61mm/h
vs. 48mm/h, p = 0.017), and lactate dehydrogenase level
(309U/L vs. 197U/L, p = 0.006). They had a lower median
hemoglobin (10.7 g/dL vs. 11.7 g/dL, p = 0.002), white
blood cell count (7.4×109/L vs. 8.5×109/L, p = 0.039), and
lymphocyte count (0.9×109/L vs. 1.1×109/L, p = 0.051).
There was no difference in mortality between
extrapulmonary and pulmonary groups. Multivariate
analysis identiﬁed age >60 years (Odds Ratio [OR] 2.4,
95% Conﬁdence interval [95%CI] 0.98 5.77, p = 0.054),
presentation with decreased general condition (OR 3.5,
95%CI 1.46 8.34, p = 0.005), hypertension (OR 2.7, 95%CI
1.16 6.38, p = 0.021), radiological old TB (OR 2.6, 95%CI
1.25 5.52, p = 0.014), and pleural effusion (OR 3.2, 95%CI
1.45 7.03, p = 0.004) as independent risk factors for
mortality.
9.1% of all cases had culture evidence of drug resistance. HIV
infection (p = 0.001) and intravenous drug usage (p = 0.001)
were the two risk factors identiﬁed.
Conclusion: There are important differences in
demographics, clinical presentation and risk factors for
extrapulmonary compared with pulmonary TB. Mortality is
related to age and co-morbidity.
OL-035 Tuberculosis disease burden in Southeast Asia
D.S. Bais1 *, R.C. Tripathi2, W. Hassan3, V.P. Singh4. 1Tongji
Medical College of HUST, China, 2Base Hospital, Army
Medical Corps, India, 3Huazhong Agriculture University,
4Lioning Medical University, China
Objectives: Tuberculosis, MTB or TB is the seventh leading
frequent cause of death worldwide among infectious
diseases. It is important to evaluate the current burden
of disease, to know how this has been changing over time.
Method: Review of current literature.
Result: According to the WHO, an estimated about 9.2
million (139/100,000 population) new cases of TB occurred
in 2006. Of these cases, 4.1 million (62/100,000 population)
were new smear positive cases. There were 14.4 million
(219/100,000 population) prevalent cases. There are 22
high-burden countries, but the majority of patients with TB
live in the eight country of Asia; India, China, Indonesia,
Bangladesh, Pakistan, Philippines, Vietnam and Afghanistan.
India is the highest TB burden country in the world
and accounts for nearly one-ﬁfth (20%) of global burden
of tuberculosis. In India, TB affects adults in the most
productive age group (15 54 years). More than 80% of TB
cases are in this group. TB kills almost 0.37 million Indian
people every year with mortality rate of about 28/100,000
population. Globally, the case detection rate by DOTS
programs increased almost linearly from 11% in 1995 to 28%
in 2000, and then accelerated to 45% in 2003. The recent
acceleration has been mostly due to rapid implementation
in India, where case detection increased from 1.7% in 1998
to 47% in 2003, and in China, where it increased from 30% in
2002 to 43% in 2003. India and China together accounted for
